Filing Flows › AstraZeneca (AZN) › Q2 2026
AstraZeneca (AZN) Q2 2026 earnings results (second quarter 2026)
6-K filed Jul 27, 2026
AstraZeneca (AZN) reported revenue of $30.7B for the second quarter 2026 (Q2 2026), +9% from a year earlier and +101% from the quarter before. Operating margin was 24.2%, net earnings $5.6B (18.2% of revenue).
AstraZeneca, Q2 2026: revenue $30.7B (+9% year over year), operating margin 24.2%, net earnings $5.6B. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $30.7B | +101% | +9% |
| Gross profit | $25.5B | +102% | +9% |
| Operating profit | $7.4B | +75% | +3% |
| Net earnings | $5.6B | +81% | +4% |
What changed
Revenue was $30.7B in Q2 2026, up 9% year over year and up 101% from the previous quarter. Oncology was the largest line at 46% of revenue.
Gross margin was 83.0%, down 0.1 points from a year earlier. Operating profit was $7.4B, a 24.2% margin (down 1.5 points year over year). Of the extra revenue versus a year earlier, 9% reached operating profit, below the 26% margin then. Operating expenses grew 12% against revenue growth of 9%. Net earnings were $5.6B, up 4% year over year. The effective tax rate was 16.7%.
Questions
What was AstraZeneca's revenue in the second quarter 2026?
AstraZeneca (AZN) reported revenue of $30.7B for the second quarter 2026 (Q2 2026), +9% from a year earlier and +101% from the quarter before.
Was AstraZeneca profitable in the second quarter 2026?
Operating profit was $7.4B (24.2% of revenue) and net earnings $5.6B.
Source: AstraZeneca 6-K on SEC EDGAR.